Loading…
NEUP
Neuphoria Therapeutics Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 64136E102
$3.76-0.27%Price as of Aug 29, 18:45 UTC · updated once a day, after the close
Key metrics
- Market cap
- $20.32M
- P/E
- —
- Forward P/E
- —
- P/B
- 0.7x
- Dividend yield
- —
- Payout
- —
- EPS
- -$7.72
- ROE
- -62.90%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- —
- 52-week high
- $21.40
- 52-week low
- $3.19
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -97.6% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Year-end price | $3.65 | $3.88 | $3.43 | $17.76 | |
| P/S | — | 16.8x | 0.6x | — | — |
| P/B | 25.9x | 0.8x | 0.5x | 50.9x | 98.8x |
| EPS | -$3.06 | -$0.23 | -$18.62 | -$0.24 | |
| Profit margin | — | -1145.66% |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CCMConcord Medical Services Holdings Ltd | $4.76 | — | — | — | -21.88% | $20.67M |
| CMMBChemomab Therapeutics Ltd. | $2.71 | — | 2.3x | — | -82.17% | $19.86M |
| AKTXAkari Therapeutics Plc | $10.70 | — | 1.0x | — | -140.09% | $20.83M |
| QNTMQuantum Biopharma Ltd. | $3.08 |
About the company
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for the treatment of cancer. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; and Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts.
- 7
- Burlington, United States
Company description provided by Yahoo Finance.